$GSK (GlaxoSmithKline plc)

$GSK {{ '2016-03-07T19:02:08+0000' | timeago}} • SEC

During 2015, $MYL recorded a $97.4MM net gain for litigation settlements vs. a net charge of $47.9MM in the prior year. The gain in 2015 was primarily related to the settlement of the Paroxetine CR matter with $GSK for approx. $113MM and the settlement of certain antitrust matters, partially offset by the settlement of patent infringement matters.

$GSK {{ '2017-07-21T15:28:58+0000' | timeago}} • Announcement

$GSK and $INVA announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta in patients with controlled asthma on an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA).

$MYL {{ '2017-05-10T15:37:21+0000' | timeago}} • Webcast

On the Advair issue, $MYL said the Food and Drug Administration (FDA) has not asked the company to do any additional clinical endpoints or device related studies. The FDA has rejected the company's generic version of Advair, a $GSK's drug to treat asthma and chronic lung conditions.

$PTX {{ '2017-03-28T20:30:42+0000' | timeago}} • Announcement

$PTX reported a wider loss in 4Q16 due primarily to non-cash charges related to the impairment of intangible assets and goodwill. Net loss widened to $86.1MM from $81.7MM a year ago. Revenue dropped 35% to $30.1MM due to negative impact of disputed rebate claims for sales related to unfavorable arbitration ruling in dispute with $GSK.

$GSK {{ '2016-08-01T15:28:44+0000' | timeago}} • Announcement

$GSK said Galvani Bioelectronics will be headquartered in the UK, with the parent companies contributing existing intellectual property rights and an investment of up to GBP 540MM over 7 years, subject to successful completion of various discovery and development milestones. This agreement is expected to close before the end of 2016.

$GSK {{ '2016-08-01T15:26:56+0000' | timeago}} • Announcement

$GSK announced an agreement with Verily Life Sciences (formerly Google Life Sciences), an $GOOG $GOOGL company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. $GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.

$MRK {{ '2016-07-29T12:17:05+0000' | timeago}} • Webcast

$MRK, which competes with rivals $GSK and $PFE, said the company's human health and animal health businesses performed well in 2Q16, delivering growth despite an approx. $210MM headwind in sales in Venezuela in 2Q15. The company said it expects adjusted OpEx for the full year to be generally in line with the prior year.

$MYL {{ '2016-06-24T16:49:55+0000' | timeago}} • Announcement

$MYL announced U.S. launch of Dutasteride Capsules, 0.5 mg, generic version of $GSK's Avodart Capsules. Mylan received final FDA approval for this product, which is indicated as monotherapy for treatment of symptomatic benign prostatic hyperplasia (BPH) in men with enlarged prostate to improve symptoms, reduce risk of acute urinary retention.

$MYL {{ '2016-06-02T13:15:02+0000' | timeago}} • Announcement

$MYL announced U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, generic version of $GSK's Rythmol SR. This is indicated to prolong time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.

$LNC {{ '2016-05-31T22:42:50+0000' | timeago}} • Announcement

$LNC said it elected Deirdre P. Connelly to serve on its BoD. Connelly served from Feb. 2009 until her retirement in Feb. 2015 as President of North American Pharmaceuticals at $GSK. Connelly currently sits on the Board of $M, a post that she has held since 2008.

$MRK {{ '2016-05-05T11:23:04+0000' | timeago}} • Announcement

$MRK, which competes with rivals $GSK and $PFE, said it expects FY16 GAAP EPS to be in the range of $1.96-2.23. $MRK narrowed and raised its FY16 non-GAAP EPS to be between $3.65-3.77, including an approx. 2% negative impact from FX at mid-April exchange rates. At mid-April exchange rates, $MRK now anticipates FY16 revenues between $39-40.2Bil.

$MYL {{ '2016-05-03T11:43:50+0000' | timeago}} • Announcement

$MYL, which competes with $PFE, $JNJ and $GSK, said it reaffirms its FY16 EPS of $2.38-2.43, the midpoint of which represents an increase of 41% compared to FY15. $MYL forecasts revenue of about $10.5-11.5Bil, the midpoint of which represents a 16% increase compared to FY15.

$GILD {{ '2016-04-28T21:03:58+0000' | timeago}} • Announcement

$GILD, which competes with $GSK and $PFE, said it reiterates its FY16 guidance. $GILD expects its FY16 diluted EPS impact from acquisitions and other expenses to be about $1.10-1.16, on revenue of about $30-31Bil. Company expects its SG&A expenses to be about $3.3-3.6Bil for the period.

$GSK {{ '2016-03-07T19:02:08+0000' | timeago}} • SEC

During 2015, $MYL recorded a $97.4MM net gain for litigation settlements vs. a net charge of $47.9MM in the prior year. The gain in 2015 was primarily related to the settlement of the Paroxetine CR matter with $GSK for approx. $113MM and the settlement of certain antitrust matters, partially offset by the settlement of patent infringement matters.

$GSK {{ '2016-02-10T22:35:41+0000' | timeago}} • Webcast

$MYL, which competes with $PFE, $JNJ and $GSK, said that R&D expense for 4Q15 and full-year 2015 rose due to the impact of the acquired EPD business and the continued development of respiratory, insulin and biologics programs. Adjusted SG&A was approx. 20% of total adjusted revenues for 4Q15 and 2015, which includes the impact of the EPD business.

$GSK {{ '2016-02-03T12:22:05+0000' | timeago}} • Announcement

$MRK, which competes with rivals $GSK and $PFE, said it expects FY16 GAAP EPS to be in the range of $1.96-2.23 and non-GAAP EPS to be in the range of $3.60-3.75, including an approx. 4% negative impact from FX. At mid-Jan. 2016 exchange rates, $MRK expects FY16 revenues to be between $38.7-40.2Bil, including an approx. 3% negative impact from FX.

$GILD {{ '2016-02-02T22:22:23+0000' | timeago}} • Webcast

$GILD, which competes with $GSK and $PFE, said it expects 2016 product sales to be $30-31Bil. Non-GAAP product gross margins are expected to be 88-90%. Non-GAAP R&D expenses are expected to be $3.2-3.5Bil, as a result of the continued investment in the company's pipeline. Non-GAAP SG&A expenses are expected to be in the range of $3.3-3.6Bil.

$GSK {{ '2015-12-18T12:58:25+0000' | timeago}} • Announcement

$GSK will pay $317MM for late-stage asset that includes fostemsavir (BMS-663068), an attachment inhibitor, currently in phase III development for heavily treatment experienced patients. $GSK will pay $33MM for purchase of preclinical and discovery stage research assets that includes a novel biologic (BMS-986197) with a triple mechanism of action.

$BMY {{ '2015-12-18T12:52:38+0000' | timeago}} • Announcement

British pharmaceutical group $GSK said it would buy the portfolio of experimental HIV drugs from its U.S. rival $BMY for a total of $1.46Bil in two transactions. $GSK expects to complete both the transactions during the first half of FY16. The deal is expected to strengthen $GSK's global HIV business ViiV Healthcare's control in the HIV market.

$AMGN {{ '2015-12-14T21:53:41+0000' | timeago}} • Announcement

$AMGN said that it has reacquired all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) & Vectibix (panitumumab) from $GSK in 48 countries. $AMGN expects this transaction to contribute to adjusted EPS in 2017. $AMGN will make undisclosed milestone payments to $GSK on signing & on successful transition of the products back to $AMGN.

$ACET {{ '2015-11-24T15:16:34+0000' | timeago}} • Announcement

$ACET said that its subsidiary, Rising Pharmaceuticals, is launching an FDA-approved generic version of $GSK's Avodart (Dutasteride) Softgel Capsules 0.5 mg in the U.S. market. According to IMS Health, U.S. market for Dutasteride, which is used for the treatment of symptomatic BPH in men with enlarged prostate, is about $452MM.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, May 9 2017 - 8:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
BCRX (BioCryst Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 3:00pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, March 14 2017 - 8:30pm
VCEL (Vericel Corporation)
Friday, March 10 2017 - 1:00pm
ARQL (ArQule Inc.)
Tuesday, March 7 2017 - 2:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm

AlphaGraphics you may like